INTRODUCTION
When Reye's syndrome was initially described, epidemiologic evidence indicated that aspirin ingestion was present during the viral illness that preceded encephalopathy and fatty liver degeneration in children [1] . After warning labels became mandatory in the 1980s warning consumers of the risk of Reye's syndrome for all aspirin-containing products, there was a marked decline in the number of reported cases [1] . Because of the danger of Reye's syndrome, alternative antipyretics such as acetaminophen (paracetamol) have become the standard of care when treating fever in infants and young children. The increased use of paracetamol starting in the 1980s and the parallel increase in atopic disorders seen over the same time period, especially in Westernized countries, led to the hypothesis of a causal relationship. Multiple studies have subsequently suggested associations between its use and the development of atopic diseases; however, results have generally been equivocal.
Mechanistically, paracetamol is thought to interfere with the natural antioxidant glutathione. Glutathione acts as a free radical scavenger, mitigating the damage caused by reactive oxygen species and serves as the major endogenous antioxidant in all human cells, including endothelial cells [2] . The concentration of glutathione in lung endothelial fluid is equivalent to the intracellular concentration [3] . In healthy human volunteers, maximum therapeutic doses of paracetamol reduce the total serum antioxidant capacity in as little as 2 weeks [4] . This perturbation in natural antioxidant activity can result in endothelial damage, especially if it were to occur during viral respiratory infections, as the host may be unable to repair oxidative damage caused by viral inflammation [5] . A similar process likely occurs in the nasal epithelium, as in-situ glutathione levels and cytotoxic damage fluctuate in response to ozone and particulate matter [6] .
Existing evidence that supports paracetamol as a risk factor for asthma is modest with odds ratios (OR) around 2, but must be interpreted with caution as specific studies do not always adjust for confounders such as respiratory infections [7, 8] . Administration of questionnaires and exposure timing also vary greatly among studies, focusing on the prenatal and the early childhood periods. Participants are often required to recall exposures over a long period of time at a single encounter [9] . Because acetaminophen is often given as an antipyretic in pregnancy and infancy during viral infections, it would seem obvious that upper respiratory infections, which are also related to atopic outcomes, are significant confounders that need to be addressed in statistical models. Multiple studies have been published that do not account for viral infections or only examine them in univariate modeling. Even large national drug and birth registries were not able to adjust for upper respiratory infections or antibiotic usage despite the data being reported in univariate models. Others were not able to account for overthe-counter use of paracetamol [10, 11] .
Although the current literature focuses heavily on asthma as an outcome, there is a paucity of epidemiologic studies examining the effect on rhinitis. The same confounders need to be examined as the upper airways represent the gateway to the lower airways and are likely to be affected by the same processes.
METHODS
A PubMed search was performed using the terms 'acetaminophen' and 'rhinitis', as well as with the terms 'acetaminophen' and 'asthma'. Both searches were limited to articles in English, yielding a total of 311 articles. Individual abstracts were reviewed for relevance to this review and were included only if one of the examined outcomes included rhinitis. Review articles were excluded, as well as articles that included rhinitis only as an effect modifier or as a predictor.
RESULTS
A large ecological study [12] of acetaminophen sales in the UK was performed between 1994 and 1995, examining atopic diseases and sales of acetaminophen in 1994 and 1995. Twelve-month prevalence of allergic rhinitis was determined using International Study of Asthma and Allergies in Children (ISAAC) questionnaires in children aged 6-7 (parental assessment) and aged 13-14 (self-assessed). This same study examined rhinitis (hay fever or nasal allergies) in adults (20-44 years old) using standardized questionnaires from the European Community Respiratory Health Survey. Paracetamol sales were obtained from hospitals, pharmacies and retailers, and used to calculate grams of paracetamol/person/year, adjusted for gross domestic product (GDP). In children and adolescents, prevalence of rhinoconjunctivitis increased about 12% for every gram increase in per capita paracetamol sales, adjusted for GDP. The relationship was greater in adults (35%). Interestingly, the authors performed a post hoc analysis controlling for the 'anglophone effect' in English-speaking countries (UK, Eire, USA, Australia, and New Zealand) and noted that all of the significant associations seen between paracetamol sales and atopic outcomes either became nonsignificant or were greatly attenuated. The authors speculate that there is likely a confounder strongly associated with English-speaking countries that is responsible for the effect. It is well known that ecological studies suffer from the fact that exposure data are not linked to individuals, and thus this study [13] design is considered to be weak and solely hypothesis generating.
In New Zealand, data from the general population showed that in 6-7-year-old children, paracetamol use in the last year (directly antecedent to the outcome assessment) at least once per month was associated with current allergic rhinoconjunctivitis {OR 1.77 [95% confidence interval (CI) 1.43-2.18]} [14] . Paracetamol use in the first year of life, however, was not associated with this outcome. Antibiotic usage during the first year of life was also associated with current allergic rhinitis [OR 2.04 (95% CI 1.60-2.61)], but there was no adjustment for upper respiratory infections during the first year of life. Although it is possible that both paracetamol use and antibiotic use in the first year of life could be surrogates for upper respiratory infections, the study
KEY POINTS
Prospective birth cohort studies and cross-sectional studies examining the role of paracetamol and its association with rhinitis are prone to the same epidemiologic pitfalls as those examining paracetamol and its association with asthma.
Evidence in the literature is modest at best, with varying degrees of accurate exposure data.
Prospective birth cohorts specifically to address paracetamol exposure need to be designed with multiple contact points in order to optimize data on exposure and to minimize recall bias.
does not adequately address this concern. Because this was not a prospective cohort study, parents were asked to recall the details about paracetamol exposure dating back at least 6 years, perhaps contributing to the lack of association seen between exposure during the first year of life and current allergic rhinoconjunctivitis symptoms.
There are multiple studies published examining rhinitis in phase 3 of the ISAAC. Adolescents (age 13-14) from 36 countries were interviewed regarding their paracetamol use, and this is impressive because of the number of participants (over 300 000) and the use of a standardized questionnaire [15] . The exposure to paracetamol (none, once, or more than once per month in the last 12 months) was measured in the year directly antecedent to the outcome of rhinoconjunctivitis, showing a modest risk (OR between 1.3 and 2.3). Although the authors did adjust for socioeconomic status, maternal smoking, and number of siblings, other early exposures such as viral infections and antibiotic exposure were not included in the models. Similarly, a Canadian phase 3 ISAAC study [16] also showed a small increased risk of rhinitis [OR 1.83 (95% CI 1.61-2.08)] in adolescents without adjustment for viral infections, and a Mexican study [17] showed increased risk of rhinitis in both 6-7 year olds [OR 1.51 (95% CI 1.31-1.75)] and in [13] [14] year olds [OR 1.31 (95% CI 1.20-1.43)]. In these last two studies, because acetaminophen use was ascertained only in the year prior to the assessment of outcome and was asked of adolescents for the entire 12 months antecedent to questionnaire administration, confounding because of viral infections cannot be ruled out and recall bias is a substantial concern.
A 10-year follow-up study of the Environment and Childhood Asthma (ECA) cohort in Oslo cohort found that maternal use of paracetamol during the first 6 months of pregnancy was associated with allergic rhinitis (doctor's diagnosis or nasal allergic symptoms in the last 12 months) at age 10 [OR 2.30 (95% CI 1.06-4.97)]. Although this was a prospective birth cohort, questions regarding paracetamol exposure were administered at the time of delivery and mothers were asked to recall their use up to 9 months prior. No prospective study has perfect methodology, but the timing of these questionnaires surrounding delivery may not be the most conducive toward gaining an accurate history, as opposed to cohorts in which mothers were recruited earlier during pregnancy [18] .
Taiwan recently switched to a large single-payer health insurance program in 1995. From this, over 200 000 children were analyzed with respect to prescription antibiotics and paracetamol use during the first year of life. The authors found an association between paracetamol use during the first year of life and allergic rhinitis for two birth cohorts [hazard ratio 1.93 (95% CI 1.85-2.02) and hazard ratio 1.42 (95% CI 1.25-1.61)] between the age of 2 and 6 years [19 && ]. Outcomes were based on the insurance claims for outpatient visits. The authors note that over-thecounter use of paracetamol was not captured in their study. They justify that most parents will not administer paracetamol in Taiwan without a prescription, but do not provide any supporting evidence.
Taken together, literature evidence supporting the association between paracetamol exposure and rhinitis is inconsistent as methodology differs among various studies. The main difficulty that seems common is the ability to obtain valid information regarding paracetamol dosage and timing during pregnancy or during the first year of life. Thus, the majority of studies must rely on paracetamol use in the year directly antecedent to the outcome assessment as most participants cannot be expected to accurately recall paracetamol use several years, or even several weeks, in retrospect. Moreover, the drug is used in many over-the-counter combination drugs. Second, viral infections as confounders are not routinely considered in statistical models.
We would like to conclude by reviewing two studies that examine atopy and asthma as examples of better-conducted cohort studies. Wickens et al. [20] demonstrated that both dose and timing of the exposure of paracetamol may determine the associations with disease outcomes. First, paracetamol use before 15 months of age was associated with atopy at age 6 (a positive skin test to a food or aeroallergen) even after adjustment for bronchial infections [OR 3.61 (95% CI 1.33-9.77)]. When examining the doses of paracetamol in the 12 months prior to the outcomes at age 6, increasing doses of paracetamol use appeared to increase risk for wheeze, current asthma, and atopy (also adjusted for bronchial infections). This suggests that paracetamol exposure early in life may be more important for the development of atopy and exposure later in life may be more important for the development of asthma. Finally, in a prospective cohort study of pregnant women, participants were recruited and interviewed before 24 weeks of gestation [21] .
Mothers were asked specifically about the paracetamol use during the first three trimesters early in their confinement to minimize recall bias, and were also queried specifically about the quantity of paracetamol use (none, 1-7 days per month, 8-14 days per month, more than 14 days per month, and everyday) in detail. Dosages were calculated in mg and the authors developed six classes of 'per month' dosages as well as four classes of 'per day' dosages. The same questions were asked 1 month postpartum. Confounders were assessed and outcome measures were collected at a 6-year follow-up. Unexpectedly, this study showed that frequent paracetamol during the first and third trimesters of pregnancy was associated with a decreased risk of asthma [OR 0.76 (95% CI 0.53-1.10)]. Cumulative (but not current) rhinitis symptoms at age 6 were also assessed in the multivariate model and were found to be significant [OR 3.23 (95% CI 2.28-4.60)]. This study [21] is notable for the amount of detail dedicated to recording paracetamol use.
CONCLUSION
It is apparent that carefully designed, hypothesistargeted prospective birth cohort studies are required to better understand the relationship between paracetamol use and rhinitis. Some existing studies do suggest increased risk with paracetamol use, but conclusions are flawed because of lack of adjustment for confounders, such as viral infections, or because of recall bias. Studies need to be designed with paracetamol as a primary predictor in mind rather than as an additional variable that happens to be collected during the administration of a questionnaire. Several contact points with participants should be planned in order to maximize the validity of exposure data and obtain detailed information on indications for medication use. Although the obvious 'best' study would be a double-blind, placebo-controlled trial using paracetamol, it would be difficult to include a placebo arm and use of another medication complicates interpretation.
